CD133+CD44+ cancer cells have been characterized in several highly metastatic tumors, such as CRCs [46-48], HCCs [49,50], pancreatic cancer [51], gallbladder carcinoma [52], lung adenocarcinomas [53] and gastric cancer [54]. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.